Previous 10 | Next 10 |
Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”). All of t...
Summary Amylyx ALS drug candidate AMX0035 has been approved in the US - it will be marketed and sold as Relyvrio. The drug has had a controversial path to approval involving 2 separate FDA Advisory Committee meetings. Initially it looked as though the FDA and its AdComm were a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Amin Van / Shutterstock.com IonQ (NYSE: IONQ ) stock is climbing higher on Friday after the company announced it secured a $13.4 million contract with the AFRL. That contract has IonQ offering its tr...
Updates price move during early regular trading The shares of Amylyx Pharmaceuticals ( NASDAQ: AMLX ) slipped ~7% on Friday morning after the company set its new FDA-approved treatment for amyotrophic lateral sclerosis at an initial annual price of $158K. AMLX sh...
The shares of Amylyx Pharmaceuticals ( NASDAQ: AMLX ) slipped pre-market Friday after the company focused on neurodegenerative diseases set its new FDA-approved treatment for amyotrophic lateral sclerosis at an initial annual price of $158K. AMLX shares surged in post-market...
RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS RELYVRIO significantly slowed loss of physical function in a randomized, placebo-controlled clinical trial in ALS Detailed data from the CENTAUR c...
The US FDA approved Amylyx Pharmaceuticals ( NASDAQ: AMLX ) Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The company's shares are up 12% in after-hours trading. Relyvrio (sodium phenylbutyrate/taurursodiol)...
Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. The trio likes Amylyx Pharmaceuticals (NASDAQ: AMLX) , a biotech with a treatment for Lou Gehrig's disease; HilleVax (NASDA...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Amylyx Pharmaceuticals, Inc. today announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial that evaluated the safety, efficacy, and survival benefits of AMX0035 in adult participants with amyotrophic lateral sclerosis (ALS) are now available in the Po...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...